# A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

> **NCT05010525** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shanghai Antengene Corporation Limited** · enrollment: 8 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ATG-016

## Key facts

- **NCT ID:** NCT05010525
- **Lead sponsor:** Shanghai Antengene Corporation Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010525, "A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05010525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*